BMEII Collaborators

Medicine & Life Sciences

1. Acute Coronary Syndrome 47%
2. Angioplasty 19%
3. Antidepressive Agents 28%
4. Anxiety Disorders 11%
5. Aorta 17%
6. Area Under Curve 12%
7. Arteries 18%
8. Aspirin 35%
9. Atherosclerosis 100%
10. Atherosclerotic Plaques 67%
11. Atrial Fibrillation 22%
12. Biomarkers 17%
13. Blood Platelets 54%
14. Blood Pressure 13%
15. Blood Vessels 32%
16. Brain 16%
17. Calcium 12%
18. Cardiac Arrhythmias 11%
19. Cardiology 11%
20. Cardiomyopathies 13%
21. Cardiovascular Diseases 60%
22. Carotid Arteries 14%
23. Cholesterol 12%
24. Clinical Trials 21%
25. Clopidogrel 12%
26. Confidence Intervals 13%
27. Contrast Media 11%
28. Coronary Artery Bypass 20%
29. Coronary Artery Disease 46%
30. Coronary Disease 32%
31. Coronary Vessels 28%
32. Coronavirus 14%
33. Depression 30%
34. Diabetes Mellitus 14%
35. Fluorodeoxyglucose F18 19%
36. Guidelines 12%
37. Health 17%
38. Health Promotion 17%
39. Heart 12%
40. Heart Diseases 11%
41. Heart Failure 19%
42. Heart Valve Diseases 13%
43. Hemorrhage 12%
44. Heparin 15%
45. Hepatocellular Carcinoma 29%
46. Hirudins 12%
47. Hydroxymethylglutaryl-CoA Reductase Inhibitors 19%
48. Hypertension 19%
49. Incidence 13%
50. Income 15%
51. Infarction 22%
52. Inflammation 25%
53. Ischemia 13%
54. Ketamine 56%
55. Life Style 12%
56. Lipids 32%
57. Liver 15%
58. Macrophages 22%
59. Magnetic Resonance Imaging 75%
60. Magnetic Resonance Spectroscopy 51%
61. Major Depressive Disorder 49%
62. Metoprolol 17%
63. Mitral Valve 11%
64. Molecular Imaging 14%
65. Mortality 21%
66. Multiparametric Magnetic Resonance Imaging 31%
67. Myocardial Infarction 61%
68. Myocardium 12%
69. Neoplasms 15%
70. Pandemics 12%
71. Pathologic Constriction 13%
72. Percutaneous Coronary Intervention 26%
73. Perfusion 21%
74. Placebos 19%
75. Platelet Aggregation Inhibitors 19%
76. Positron-Emission Tomography 22%
77. Post-Traumatic Stress Disorders 19%
78. Primary Prevention 12%
79. Prostate 11%
80. Prostatic Neoplasms 15%
81. Pulmonary Hypertension 25%
82. Rabbits 17%
83. Randomized Controlled Trials 19%
84. Reperfusion 18%
85. Rupture 25%
86. Secondary Prevention 22%
87. ST Elevation Myocardial Infarction 14%
88. Stroke 35%
89. Swine 34%
90. Therapeutics 46%
91. Thrombin 16%
92. Thromboembolism 12%
93. Thromboplastin 16%
94. Thrombosis 69%
95. Tomography 23%
96. Transplants 11%
97. Treatment-Resistant Depressive Disorder 40%
98. Unstable Angina 28%
99. Warfarin 16%
100. Wounds and Injuries 17%